712-52-7

Basic information

• Product Name: BROMO-(4-FLUORO-PHENYL)-ACETIC ACID ETHYL ESTER
• Synonyms: BROMO-(4-FLUORO-PHENYL)-ACETIC ACID ETHYL ESTER;ETHYL BROMO-(4-FLUORO-PHENYL)-ACETATE;Benzeneacetic acid, .alpha.-broMo-4-fluoro-, ethyl ester
• CAS NO: 712-52-7
• Molecular Formula: C₁₀H₁₀BrFO₂
• Molecular Weight: 261.0876032
• Mol File: 712-52-7.mol

Chemical Properties

• Boiling Point: 270.4°C at 760 mmHg
• Flash Point: 117.3°C
• Appearance: /
• Density: 1.476g/cm³
• Vapor Pressure: 0.00685mmHg at 25°C
• Refractive Index: 1.529
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: BROMO-(4-FLUORO-PHENYL)-ACETIC ACID ETHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: BROMO-(4-FLUORO-PHENYL)-ACETIC ACID ETHYL ESTER(712-52-7)
• EPA Substance Registry System: BROMO-(4-FLUORO-PHENYL)-ACETIC ACID ETHYL ESTER(712-52-7)

Safety Data

• Hazardous Substances Data: 712-52-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
BROMO-(4-FLUORO-PHENYL)-ACETIC ACID ETHYL ESTER is used as a building block for the synthesis of various pharmaceuticals. Its unique structure allows for the creation of a wide range of medicinal compounds with potential therapeutic applications.
Used in Organic Synthesis:
In the field of organic synthesis, BROMO-(4-FLUORO-PHENYL)-ACETIC ACID ETHYL ESTER is used as a reagent in chemical reactions. Its ethyl ester form provides greater solubility, making it easier to incorporate into various organic compounds and facilitating the synthesis process.
Used in Research and Development:
BROMO-(4-FLUORO-PHENYL)-ACETIC ACID ETHYL ESTER is also utilized in research and development settings, where its unique properties and reactivity are explored for potential applications in new chemical processes and the discovery of novel compounds.

InChI:InChI=1/C10H10BrFO2/c1-2-14-10(13)9(11)7-3-5-8(12)6-4-7/h3-6,9H,2H2,1H3

Upstream product

• 587-88-2 ethyl 2-(4-fluorophenyl)acetate 
• 462-06-6 fluorobenzene 
• 1813-94-1 ethyl 4-fluorobenzoylformate 
• 7550-03-0 ethyl 2-(4-fluorophenyl)-2-hydroxyacetate 
• 64-17-5 ethanol 
• 29270-33-5 2-bromo-2-(4-fluorophenyl)acetic acid 

Downstream Products

• 220531-17-9 (4-Fluoro-phenyl)-(4-nitro-imidazol-1-yl)-acetic acid ethyl ester 
• 1446252-34-1 (E)-ethyl 3-(2-(tert-butoxycarbonylamino)pyridin-4-yl)-2-(4-fluorophenyl) acrylate 
• 1446252-35-2 (E)-2-(4-fluorophenyl)-3-( pyridin-4-yl)acrylic acid 
• 1446252-37-4 (E)-ethyl 3-(2-aminopyridine-4-yl)-2-(4-fluorophenyl)acrylate 
• 1446252-38-5 (E)-ethyl 2-(4-fluorophenyl)-3-(2-(isopropylamino)pyridin-4-yl)acrylate 
• 1446252-39-6 3-[2-(tert-butoxycarbonyl-isopropyl-amino)-pyridin-4-yl]-2-(4-fluoro-phenyl)-acrylic acid ethyl ester 
• 1813-94-1 ethyl 4-fluorobenzoylformate 
• 366018-91-9 ethyl 2-amino-2-(4-fluorophenyl)acetate 
• 1398003-99-0 cis-t-butyl-2-methoxy-3,5-dioxane-6-amino-(N-ethyl-(4-fluorobenzene)-acetate)-heptanoate 

Relevant articles and documents

ANTIVIRAL COMPOUNDS

The present invention relates to novel compounds of general formula (I) wherein R1 to R4 and n have the meanings given in the description and claims, process for preparing these compounds and their use as for treating, preventing or ameliorating viral infections and their use for treating, preventing or ameliorating diseases which are associated with PLA2G16.

Pd-catalyzed divergent C(sp2)-H Activation/Cycloimidoylation of 2-Isocyano-2,3-diarylpropanoates

A Pd-catalyzed site-selective C(sp2)-H activation/cycloimidoylation of 2-isocyano-2,3-diarylpropanoates to construct diverse cyclic imine products has been developed. Six-membered 3,4-dihydroisoquinolines containing a C3 quaternary carbon cente

MGLUR7 AGONIST COMPOUNDS FOR TREATING MGLUR7- REGULATED DISEASES, DISORDERS, OR CONDITIONS

The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof wherein Z, R1, R2, R3, R4, R5 and R6 are as defined in the specification, a process for

Azastilbenes: A cut-off to p38 MAPK inhibitors

Inhibitors with vicinal 4-fluorophenyl/4-pyridine rings on a five- or six-membered heterocyclic ring are known to inhibit the p38 mitogen-activated protein kinase (MAPK), which is a potential target for rheumatoid arthritis and several different types of cancer. Several substituted azastilbene-based compounds with vicinal 4-fluorophenyl/4-pyridine rings were designed using computational docking, synthesized, and evaluated in a cell-free radiometric p38α assay. The biochemical evaluation shows that the best inhibition (down to 110 nM) is achieved for azastilbene-based compounds having an isopropylamine substituent in the 2-position of the pyridine ring. The inhibition of p38 signaling in human breast cancer cells was observed for two of the compounds. The Royal Society of Chemistry 2013.

Method for treating emesis with ghrelin agonists

The present invention relates to a method comprising administering to a patient diagnosed as being in need of treatment for nausea, emesis, or symptoms associated therewith comprising administering to a patient in need thereof a compound of formula (I) wh

Growth hormone secretagogues

What is disclosed are growth hormone secretagogues, and their uses, of the formula wherein R1 is C6H5CH2OCH2—, C6H5(CH2)3— or indol-3-ylmethyl; Y is pyrrolidin-1-yl, 4-C1-C6alkylpiperidin-1-yl or NR2R2; R2 are each independently a C1to C6alkyl; R3 is 2-napthyl or phenyl para-substituted by W; W is H, F, CF3, C1-C6alkoxy or phenyl; and R4 is H or CH3, or a pharmaceutically acceptable salt or solvate thereof.